Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom.
An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42-66); age-specific adjusted VE was 87% (95% CI 45-97) in <5-year-olds and 84% (95% CI 27-97) in 5- to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI -6 to 51) overall and 72% (95% CI 15-91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42-68) and in 5- to 14-year-olds 75% (95% CI 32-91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.
Health Protection Agency Health Protection Services - Colindale, London, UK.
R G
RG
Pebody
Health Protection Agency Health Protection Services - Colindale, London, UK.
N
N
Andrews
Royal College of General Practitioners Research and Surveillance Centre, Birmingham, UK.
D M
DM
Fleming
Health Protection Scotland, Glasgow, UK.
J
J
McMenamin
Public Health Wales, Cardiff, UK.
S
S
Cottrell
Public Health Agency Northern Ireland, Belfast, UK.
B
B
Smyth
Royal College of General Practitioners Research and Surveillance Centre, Birmingham, UK.
H
H
Durnall
Health Protection Scotland, Glasgow, UK.
C
C
Robertson
West of Scotland Specialist Virology Centre, Glasgow, UK.
W
W
Carman
Health Protection Agency Microbiology Services - Colindale, London, UK.
J
J
Ellis
Health Protection Agency Microbiology Services - Colindale, London, UK.
P
P
Sebastian-Pillai
Health Protection Agency Microbiology Services - Colindale, London, UK.
M
M
Zambon
Public Health Agency Northern Ireland, Belfast, UK.
C
C
Kearns
Public Health Wales, Cardiff, UK.
C
C
Moore
Public Health Wales, Cardiff, UK.
D Rh
DR
Thomas
Health Protection Agency Health Protection Services - Colindale, London, UK.
J M
JM
Watson
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D009981:Influenza B virus; D007252:Influenza Vaccines; D007251:Influenza, Human / Q000453:epidemiology* / Q000517:prevention & control* / Q000821:virology; D008297:Male; D008875:Middle Aged; D058873:Pandemics; D006113:United Kingdom / Q000453:epidemiology; D055815:Young Adult
D007252:Influenza Vaccines